Seminars in Hematology
Volume 40, Issue 1 , Pages 72-78 , January 2003

Autografting in chronic myeloid leukemia

References 

  1. Bergamaschi G, Podestà M, Frassoni F, et al.  Restoration of normal polyclonal hemopoiesis in patients with chronic myeloid leukemia autografted with Ph1-negative peripheral stem cells. Br J Haematol. 1994;87:867–870
  2. Breems DA, van Hennik PB, Kusadasi N, et al.  Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells. Blood. 1996;87:5370–5378
  3. Carella AM, Cunningham I, Lerma E, et al.  Mobilization and transplantation of Philadelphia-negative peripheral blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol. 1997;15:1575–1582
  4. Carella AM, Dejana A, Lerma E, et al.  In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol. 1996;95:127–130
  5. Carella AM, Frassoni F, Pollicardo N, et al.  Philadelphia-chromosome-negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome-positive acute lymphoblastic leukemia. Br J Haematol. 1995;89:535–538
  6. Carella AM, Lerma E, Corsetti MT, et al.  Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood. 1999;93:1534–1539
  7. Carella AM, Simonsson B, Link H, et al.  Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha. Br J Haematol. 1998;101:111–118
  8. Chalmers EA, Franklin IM, Kelsey SM, et al.  Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: Mobilization of Philadelphia-negative peripheral blood stem cells. Br J Haematol. 1997;96:627–634
  9. Corsetti MT, Lerma E, Dejana A, et al.  Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft. Exp Hematol. 2000;28:104–111
  10. Coulombel L, Kalousek DK, Eaves CJ, et al.  Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukaemia. N Engl J Med. 1983;308:1493–1498
  11. Cross NCP, Feng L, Chase A, et al.  Competitive polymerase chain reaction to estimate the number of BCR/ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993;82:1926–1936
  12. Druker BJ, Talpaz M, Resta R, et al.  Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as target therapy for chronic myelogenous leukemia. Blood. 1999;94(suppl 1, abstr):368a
  13. Druker BJ, Tamura S, Buchdunger E, et al.  Effect of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med. 1996;2:561–566
  14. Dube ID, Arlin ZA, Kalousek DK, et al.  Non-clonal hematopoietic progenitor cells detected in long-term marrow cultures from a Turner syndrome mosaic with chronic myeloid leukemia. Blood. 1984;64:1284–1287
  15. Fisher T, Neubauer A, Mohm J, et al.  Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied. Ann Hematol. 1998;77:21–26
  16. Goldman J. The decision whether to allograft a patient with CML. In:  Carella AM,  Daley GQ,  Eaves CJ, et al. editor. Chronic Myeloid Leukaemia: Biology and Treatment. London, UK: Martin Dunitz; 2002;p. 263–271
  17. Goto T, Nishikori M, Arlin Z, et al.  Growth characteristics of leukemic and normal hematopoietic cells in Ph+ chronic myelogenous leukemia and effects of intensive treatment. Blood. 1982;59:793–808
  18. Heinzinger M, Waller CF, Rosenstiel A, et al.  Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML. Leukemia. 1998;12:333–339
  19. Ho AD, Young D, Maruyama M, et al.  Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both. Exp Hematol. 1996;24:1460–1468
  20. Hochhaus A, Reiter A, Saussele S, et al.  Molecular heterogeneity in complete cytogenetic responders after Interferon-α therapy for chronic myeloid leukemia: Low levels of minimal residual disease are associated with continuing remission. Blood. 2000;95:62–66
  21. Hogge DE, Coulombel L, Kalousek DK, et al.  Non-clonal hematopoietic progenitors in a G6PD heterozygote with chronic myelogenous leukemia revealed after long-term marrow culture. Am J Hematol. 1987;24:389–394
  22. Holyoake T, Jiang X, Eaves C, et al.  Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999;94:2056–2064
  23. Johnson RJ, Owen RG, Child JA, et al.  Mobilization of Philadelphia-negative peripheral blood mononuclear cells in chronic myeloid leukaemia using hydroxyurea and G-CSF (filgrastim). Br J Haematol. 1996;93:863–868
  24. Kantarjian HM, Cortes J, O'Brien S, et al.  Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547–3553
  25. Kantarjian HM, Talpaz M, Hester J, et al.  Collection of peripheral blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive chemotherapy. J Clin Oncol. 1995;13:553–559
  26. Kantarjian HM, Vellekoop L, McCredie KB, et al.  Intensive combination chemotherapy (ROAP 10) and splenectomy in management of chronic myelogenous leukemia. J Clin Oncol. 1985;3:192–200
  27. Lennard A, Storey N, Dickinson AM, et al.  Collection of Philadelphia-negative peripheral blood progenitor cells in unselected patients with chronic granulocytic leukaemia. Northern Regional Haematology Group. Leukemia. 1998;12:746–752
  28. Morton J, Mollee P, Taylor K, et al.  Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor. Leuk Res. 1999;23:177–183
  29. Podestà M, Piaggio G, Frassoni F, et al.  Very primitive hemopoietic cells (LTC-IC) are present in Philadelphia negative cytaphereses collected during early recovery after chemotherapy for chronic myelogenous leukemia. Bone Marrow Transplant. 1995;16:549–555
  30. Prosper F, Stroneck D, Verfaillie CM. Phenotypic and functional characterization of long-term culture-initiating cells in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor. Blood. 1996;88:2033–2042
  31. Sureda A, Petit J, Brunet S, et al.  Mini-ICE regimen as mobilization therapy for chronic myelogenous leukaemia patients at diagnosis. Bone Marrow Transplant. 1999;12:1285–1290
  32. Sutherland HJ, Eaves CJ, Eaves AC, et al.  Characterization and partial purification of human marrow cells capable of initiating long-term hematopiesis in vitro. Blood. 1989;74:1563–1570
  33. Talpaz M, Kantarjian H, Kurzrock R, et al.  Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients. Ann Intern Med. 1991;114:532–538
  34. Talpaz M, Silver RT, Druker BJ, et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood. 2002;99:1928–1937
  35. Turhan AG, Humphries RK, Eaves CJ, et al.  Detection of breakpoint cluster region-negative and nonclonal hematopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow. Blood. 1990;76:2404–2410
  36. Van den Berg D, Wessman M, Murray L, et al.  Leukemic burden in subpopulations of CD34+ cells isolated from the mobilised peripheral blood of alfa-interferon-resistant or intolerant patients with chronic myeloid leukemia. Blood. 1996;87:4348–4357
  37. Verfaillie CM, Bhatia R, Steinbuch M, et al.  Comparative analysis of autografting in chronic myelogenous leukemia: Effects of priming regimen and marrow or blood origin of stem cells. Blood. 1998;92:1820–1831
  38. Waller CF, Heinzinger M, Rosenstiel A, et al.  Mobilization and transplantation of Philadelphia chromosome-negative peripheral blood progenitor cells in patients with CML. Br J Haematol. 1998;103:227–234
  39. Wang JCY, Lapidot T, Cashman JD, et al.  High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukaemia in chronic phase. Blood. 1998;91:2406–2414
  40. Weaver A, Ryder D, Crowther D, et al.  Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administrated in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood. 1996;88:3323–3328

☆ Supported by “Un Taglio per la vita.”

☆☆ Address reprint requests to Angelo M. Carella, MD, IRCCS, Ospedale “Casa Sollievo della Sofferenza,” Department of Hematology/Oncology-Viale Cappuccini, 71013 San Giovanni Rotondo (FG), Italy.

PII: S0037-1963(03)70044-4

Seminars in Hematology
Volume 40, Issue 1 , Pages 72-78 , January 2003

Article Tools

* Image Usage & Resolution